- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
Patent holdings for IPC class A61P 7/04
Total number of patents in this class: 1715
10-year publication summary
48
|
58
|
99
|
128
|
116
|
162
|
140
|
180
|
128
|
76
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bioverativ Therapeutics Inc. | 213 |
53 |
Chugai Seiyaku Kabushiki Kaisha | 1357 |
29 |
Cellphire, Inc. | 115 |
27 |
The Children's Hospital of Philadelphia | 789 |
25 |
Takeda Pharmaceutical Company Limited | 2709 |
23 |
Genzyme Corporation | 1261 |
21 |
Novo Nordisk A/S | 2284 |
20 |
Laboratoire Francais du Fractionnement et des Biotechnologies | 294 |
17 |
CSL Behring Lengnau AG | 126 |
17 |
Baxter International Inc. | 2397 |
16 |
Baxter Healthcare S.A. | 1825 |
15 |
Novo Nordisk Health Care AG | 341 |
15 |
Pfizer Inc. | 3381 |
13 |
Cantab Biopharmaceuticals Patents Limited | 23 |
13 |
Baxalta Incorporated | 302 |
12 |
CSL Behring GmbH | 345 |
11 |
The University of North Carolina at Chapel Hill | 2039 |
11 |
The General Hospital Corporation | 4731 |
10 |
CSL Limited | 253 |
10 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3366 |
10 |
Other owners | 1347 |